Work

543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.657

Authors: A. Drilon, L. Paz-Ares, R.C. Doebele, A.F. Farago, S.V. Liu, S.P. Chawla, D. Tosi, C.M. Blakely, J.C. Krauss, L. Bazhenova, T. John, B. Besse, J. Wolf, T. Seto, B.C. Cho, C. Rolfo, S. Osborne, A. Aziez, G.D. Demetri

Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Hospital Universitario 12 De Octubre, University of Colorado Anschutz, Massachusetts General Hospital, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Sarcoma Oncology Center, Inserm, Université de Montpellier, Institut de Recherche en Cancérologie de Montpellier, University of California, San Francisco, University of Michigan, University of California San Diego, Moores Cancer Center, Austin Health, Olivia Newton-John Cancer Research Institute, Institut Gustave Roussy, Fondation Gustave Roussy, University Hospital Cologne, National Hospital Organization Kyushu Cancer Center, Yonsei Cancer Hospital, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, F. Hoffmann-La Roche AG, Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3087895176

FWCI: 1.409

Cites:

Cited by: 11

Related to: 10